Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Plos One
|
February 25, 2017
Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure
Maureen J Kimulwo, Javan Okendo, Rashid A Aman, et al.
Brazilian Journal of Biology = Revista Brasleira De Biologia
|
September 15, 2021
Glycogen synthase kinase-3 (GSK-3) a magic enzyme: it's role in diabetes mellitus and glucose homeostasis, interactions with fluroquionlones. A mini-review
A Ullah, N Ali, S Ahmad, et al.
Neuroscience Research
|
January 2, 2021
WITHDRAWN: Evaluation of the factors that may contribute to the responsiveness of anti-epileptic treatments in pediatric patients, a study from Jordan
Nasr N Alrabadi, Laith N Al-Eitan, Islam M Al-Dalalah, et al.
Cureus
|
March 28, 2025
Treatment Modalities and Survival Outcomes in Gastric Cancer: Insights From Najran, Saudi Arabia
Ahmed M Badheeb, Ibrahim A Alyami, Ahlam Y Alyami, et al.
Cureus
|
May 21, 2024
Clinical and Therapeutic Characteristics of Hospitalized Patients with Advanced Lung Cancer in Najran, Saudi Arabia: A Retrospective Study
Ahmed M Badheeb, Hamoud Y Obied, Mohammed Al Suleiman, et al.
Cureus
|
August 16, 2024
Factors Affecting Length of Stays in the Emergency Department of a Teaching Hospital: A Retrospective Study From Najran, Saudi Arabia
Ahmed M Badheeb, Mohammed A Almutairi, Abbas H Almakrami, et al.
Cureus
|
July 29, 2024
Cancer Care During the COVID-19 Pandemic: A Retrospective Study From a Najran Oncology Center
Ahmed M Badheeb, Sarah H Musallam, Ahlam Y Alyami, et al.
Cell Death & Disease
|
July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing
Z Wang, P Dove, X Wang, et al.
Cureus
|
November 25, 2024
Clinical Characteristics and Treatment Outcomes of Thyroid Cancer at a Tertiary Care Hospital in Najran Region, Saudi Arabia: A Single-Centre Retrospective Study
Ahmed M Badheeb, Samer Alkarak, Mana A Alhajlan, et al.
JCO Global Oncology
|
February 4, 2021
Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia
Soehartati Gondhowiardjo, Nadia Christina, Ngakan P D Ganapati, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Plos One
|
February 25, 2017
Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure
Maureen J Kimulwo, Javan Okendo, Rashid A Aman, et al.
Brazilian Journal of Biology = Revista Brasleira De Biologia
|
September 15, 2021
Glycogen synthase kinase-3 (GSK-3) a magic enzyme: it's role in diabetes mellitus and glucose homeostasis, interactions with fluroquionlones. A mini-review
A Ullah, N Ali, S Ahmad, et al.
Neuroscience Research
|
January 2, 2021
WITHDRAWN: Evaluation of the factors that may contribute to the responsiveness of anti-epileptic treatments in pediatric patients, a study from Jordan
Nasr N Alrabadi, Laith N Al-Eitan, Islam M Al-Dalalah, et al.
Cureus
|
March 28, 2025
Treatment Modalities and Survival Outcomes in Gastric Cancer: Insights From Najran, Saudi Arabia
Ahmed M Badheeb, Ibrahim A Alyami, Ahlam Y Alyami, et al.
Cureus
|
May 21, 2024
Clinical and Therapeutic Characteristics of Hospitalized Patients with Advanced Lung Cancer in Najran, Saudi Arabia: A Retrospective Study
Ahmed M Badheeb, Hamoud Y Obied, Mohammed Al Suleiman, et al.
Cureus
|
August 16, 2024
Factors Affecting Length of Stays in the Emergency Department of a Teaching Hospital: A Retrospective Study From Najran, Saudi Arabia
Ahmed M Badheeb, Mohammed A Almutairi, Abbas H Almakrami, et al.
Cureus
|
July 29, 2024
Cancer Care During the COVID-19 Pandemic: A Retrospective Study From a Najran Oncology Center
Ahmed M Badheeb, Sarah H Musallam, Ahlam Y Alyami, et al.
Cell Death & Disease
|
July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing
Z Wang, P Dove, X Wang, et al.
Cureus
|
November 25, 2024
Clinical Characteristics and Treatment Outcomes of Thyroid Cancer at a Tertiary Care Hospital in Najran Region, Saudi Arabia: A Single-Centre Retrospective Study
Ahmed M Badheeb, Samer Alkarak, Mana A Alhajlan, et al.
JCO Global Oncology
|
February 4, 2021
Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia
Soehartati Gondhowiardjo, Nadia Christina, Ngakan P D Ganapati, et al.
Page
of 7